Immix Biopharma (NASDAQ:IMMX) Now Covered by Needham & Company LLC

Needham & Company LLC started coverage on shares of Immix Biopharma (NASDAQ:IMMX) in a report issued on Wednesday, Marketbeat reports. The firm issued a buy rating and a $21.00 price target on the stock.

IMMX has been the topic of several other reports. Citigroup assumed coverage on Immix Biopharma in a report on Thursday, June 18th. They set a “buy” rating on the stock. HC Wainwright boosted their price target on Immix Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, May 22nd. Citizens Jmp reaffirmed a “market outperform” rating and set a $23.00 price objective on shares of Immix Biopharma in a research report on Friday, March 27th. Lifesci Capital began coverage on shares of Immix Biopharma in a research report on Wednesday, June 17th. They set an “outperform” rating and a $19.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research note on Friday, July 17th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.71.

Immix Biopharma Trading Down 1.7%

Shares of IMMX stock opened at $9.41 on Wednesday. The stock has a market cap of $512.00 million, a P/E ratio of -10.23 and a beta of 0.09. Immix Biopharma has a 1 year low of $1.94 and a 1 year high of $12.14. The stock has a 50 day simple moving average of $9.42 and a 200 day simple moving average of $8.51.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. Analysts forecast that Immix Biopharma will post -0.69 EPS for the current year.

Institutional Investors Weigh In On Immix Biopharma

A number of large investors have recently modified their holdings of IMMX. Janus Henderson Group PLC increased its stake in shares of Immix Biopharma by 22.5% in the 1st quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock valued at $43,698,000 after purchasing an additional 880,434 shares during the last quarter. Eventide Asset Management LLC bought a new stake in shares of Immix Biopharma during the 4th quarter worth $13,331,000. Marshall Wace LLP lifted its position in shares of Immix Biopharma by 3,495.4% during the 4th quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock worth $10,349,000 after buying an additional 1,923,708 shares during the last quarter. Millennium Management LLC acquired a new stake in Immix Biopharma in the fourth quarter valued at about $8,681,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in Immix Biopharma in the fourth quarter valued at about $7,845,000. Institutional investors and hedge funds own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.